Ionis Pharmaceuticals, Inc. (IONS)
58.09
-0.04
(-0.07%)
USD |
NASDAQ |
Sep 04, 16:00
51.90
-6.19
(-10.66%)
After-Hours: 20:00
Ionis Pharmaceuticals Research and Development Expense (Quarterly) : 216.41M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 216.41M |
| March 31, 2026 | 210.17M |
| December 31, 2025 | 279.36M |
| September 30, 2025 | 217.13M |
| June 30, 2025 | 216.86M |
| March 31, 2025 | 200.76M |
| December 31, 2024 | 245.00M |
| September 30, 2024 | 219.76M |
| June 30, 2024 | 222.06M |
| March 31, 2024 | 214.22M |
| December 31, 2023 | 257.00M |
| September 30, 2023 | 215.33M |
| June 30, 2023 | 229.93M |
| March 31, 2023 | 197.81M |
| December 31, 2022 | 308.00M |
| September 30, 2022 | 182.99M |
| June 30, 2022 | 180.76M |
| March 31, 2022 | 161.13M |
| December 31, 2021 | 179.00M |
| September 30, 2021 | 184.77M |
| June 30, 2021 | 139.31M |
| March 31, 2021 | 139.80M |
| December 31, 2020 | 171.00M |
| September 30, 2020 | 125.08M |
| June 30, 2020 | 122.26M |
| Date | Value |
|---|---|
| March 31, 2020 | 116.95M |
| December 31, 2019 | 148.61M |
| September 30, 2019 | 104.24M |
| June 30, 2019 | 106.03M |
| March 31, 2019 | 106.30M |
| December 31, 2018 | 113.33M |
| September 30, 2018 | 95.14M |
| June 30, 2018 | 101.73M |
| March 31, 2018 | 103.97M |
| December 31, 2017 | 128.21M |
| September 30, 2017 | 80.16M |
| June 30, 2017 | 83.45M |
| March 31, 2017 | 82.57M |
| December 31, 2016 | 101.08M |
| September 30, 2016 | 83.87M |
| June 30, 2016 | 77.42M |
| March 31, 2016 | 80.51M |
| December 31, 2015 | 100.04M |
| September 30, 2015 | 87.98M |
| June 30, 2015 | 67.46M |
| March 31, 2015 | 63.90M |
| December 31, 2014 | 67.41M |
| September 30, 2014 | 60.54M |
| June 30, 2014 | 58.69M |
| March 31, 2014 | 52.88M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 413.13M |
| Biogen, Inc. | 461.70M |
| BridgeBio Pharma, Inc. | 149.45M |
| Vertex Pharmaceuticals, Inc. | 993.80M |
| Arrowhead Pharmaceuticals, Inc. | 192.06M |